Sanofi-Aventis Announces Withdrawal of NDA
Sanofi-aventis said it withdrew its new drug application (NDA) for the obesity drug rimonabant in the U.S.
Sanofi-aventis said it has confidence in the positive benefit-risk ratio of rimonabant 20 mg when used in the appropriate population.
The company said it will work with the FDA to make any required modifications to its filing so that it may file another NDA.
According to the company, rimonabant is approved in 42 countries.